ABSTRACT
Background SARS-CoV-2 causes COVID-19, which can be fatal and is responsible for a global pandemic. Variants with increased transmissibility or the potential to evade immunity have emerged and represent a threat to global pandemic control. Variants of concern (VOC) can be identified by sequencing of viral RNA, or by more rapid methods for detection of subsets of signature mutations.
Methods We developed a multiplex, real-time RT-PCR assay (cobas® SARS-CoV-2 Variant Set 1) for the qualitative detection and differentiation of three key SARS-CoV-2 mutations in the viral spike protein: del 69-70, E484K and N501Y. Analytical sensitivity and accuracy were evaluated at three testing sites using clinical specimens from patients infected with SARS-CoV-2 variants belonging to several different lineages, including B.1.1.7, B.1.351, and P.1.
Results The limit of detection for E484K was between 180 and 620 IU/mL for the three different isolates tested. For N501Y, the LOD was between 270 and 720 IU/mL (five isolates), while for del 69-70, it was 80 - 92 IU/mL (two isolates). Valid test results were obtained with all clinical specimens that were positive using routine diagnostic tests. Compared to sequencing (Sanger and next-generation), test results were 100% concordant at all three loci; no false positive or false negative results were observed.
Conclusions Data collected at three independent laboratories indicates excellent performance and concordance of cobas® SARS-CoV-2 Variant Set 1 with sequencing. New sets of primers and probes that target additional loci can be rapidly deployed in response to the identification of other emerging variants.
Competing Interest Statement
J.C., D.D., A.K., C.M., C.S., J.S., G.S. and C.S. are employees of Roche Molecular Systems. C.B. is an employee of Roche Diagnostics International AG.
Funding Statement
This study was funded by Roche Molecular Systems and Programm des bayerischen Staatsministeriums fur Wissenschaft und Kunst zur Forderung von Corona-Forschungsprojekten (University Hospital Regensburg).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Remnant, de-identified patient specimens were collected and used according to ethics committee regulations in effect at each site. All specimens, initially tested for SARS-CoV-2 as part of routine screening in Germany, were left-over samples that were de-identified before being tested with the new Variant Set 1 test. The study was conducted in accordance with applicable regulations, including relevant European Union directives and regulations, and the principles of the Declaration of Helsinki. For studies with anonymized left-over specimens, ethics committee vote is not typically required. A statement was obtained from the Ethics Committee of the Landesarztekammer Bavaria confirming that there are no objections to the transfer and coherent use of anonymized leftover samples. In addition, at the University Hospital of Regensburg the study was approved by the ethical committee of the Faculty for Medicine, University of Regensburg (ref. no. 20-1854-101), Labor Berlin (ref. no. Unser Zeichen Eth-19/21 MA) and Bioscentia Ingelheim (ref. no. 2021-15815).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos